Enterprise Value

-200.8M

Cash

658.9M

Avg Qtr Burn

-37.77M

Short % of Float

11.28%

Insider Ownership

9.34%

Institutional Own.

82.20%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
HEMGENIX® (etranacogene dezaparvovec-drlb) (AMT-061) Details
Hemophilia, Rare diseases, Rare genetic disease

Approved

Quarterly sales

AMT-130 Details
Huntington's disease, Genetic disorder

Phase 1/2

Update

AMT-260 Details
Mesial temporal lobe epilepsy, Epilepsy

Phase 1/2

Update

AMT-162 Details
Amyotrophic lateral sclerosis

Phase 1/2

Initiation

AMT-191 Details
Fabry disease, Genetic disorder

IND

Submission